Oral Kaposi's sarcoma: a review and update
Identifieur interne : 006B93 ( Istex/Corpus ); précédent : 006B92; suivant : 006B94Oral Kaposi's sarcoma: a review and update
Auteurs : Mahnaz Fatahzadeh ; Robert A. SchwartzSource :
- International Journal of Dermatology [ 0011-9059 ] ; 2013-06.
Abstract
Kaposi's sarcoma (KS) is an important mucocutaneous neoplasm with four well‐known clinicopathologic types. Involvement of the oral cavity may be seen in all variants but is most common with AIDS‐KS. The latter may signal undiagnosed HIV infection. Its common association with disseminated disease has potentially important diagnostic and therapeutic implications. Oral KS (OKS) most often affects the hard and soft palate, gingiva, and dorsal tongue with plaques or tumors of coloration ranging from non‐pigmented to brownish‐red or violaceous. Its involvement ranges from an incidental finding to proliferative tumor formation that interferes with mastication. OKS needs to be distinguished clinically from other entities, including pyogenic granuloma, hemangioma, bacillary angiomatosis, and gingival enlargement caused by cyclosporine, a drug frequently used in recipients of organ transplantation. KS may flare as part of the immune reconstitution inflammatory syndrome in HIV patients or develop in the context of iatrogenic immunosuppression. Management, which may depend upon a variety of factors including the clinicopathologic type of KS and results of staging, ranges from no treatment to local measures such as intralesional vinblastine or systemic administration of cytotoxic chemotherapy for disseminated disease. Modification of immunosuppressive regimens often helps control post‐transplant OKS but enhances the risk of graft rejection. Screening donors and recipients of organ transplants for HHV‐8, with prophylactic treatment if infected as well as institution of sirolimus early after transplantation, are proposed strategies aimed at preventing post‐transplant OKS.
Url:
DOI: 10.1111/j.1365-4632.2012.05758.x
Links to Exploration step
ISTEX:E5C9A6A162C267E19069C7F79B67AE9D96EFC3EALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Oral Kaposi's sarcoma: a review and update</title><author><name sortKey="Fatahzadeh, Mahnaz" sort="Fatahzadeh, Mahnaz" uniqKey="Fatahzadeh M" first="Mahnaz" last="Fatahzadeh">Mahnaz Fatahzadeh</name><affiliation><mods:affiliation>Oral Medicine, New Jersey Dental School, NJ, Newark, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mahnaz Fatahzadeh, ,Division of Oral MedicineNew Jersey Dental School110 Bergen StreetNewark, NJ 07103‐2714, USAE‐mail: </mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: fatahza@umdnj.edu</mods:affiliation></affiliation></author><author><name sortKey="Schwartz, Robert A" sort="Schwartz, Robert A" uniqKey="Schwartz R" first="Robert A." last="Schwartz">Robert A. Schwartz</name><affiliation><mods:affiliation>Dermatology and Pathology, New Jersey Medical School, NJ, Newark, USA</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA</idno><date when="2013" year="2013">2013</date><idno type="doi">10.1111/j.1365-4632.2012.05758.x</idno><idno type="url">https://api.istex.fr/document/E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">006B93</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">006B93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Oral Kaposi's sarcoma: a review and update</title><author><name sortKey="Fatahzadeh, Mahnaz" sort="Fatahzadeh, Mahnaz" uniqKey="Fatahzadeh M" first="Mahnaz" last="Fatahzadeh">Mahnaz Fatahzadeh</name><affiliation><mods:affiliation>Oral Medicine, New Jersey Dental School, NJ, Newark, USA</mods:affiliation></affiliation><affiliation><mods:affiliation>Mahnaz Fatahzadeh, ,Division of Oral MedicineNew Jersey Dental School110 Bergen StreetNewark, NJ 07103‐2714, USAE‐mail: </mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: fatahza@umdnj.edu</mods:affiliation></affiliation></author><author><name sortKey="Schwartz, Robert A" sort="Schwartz, Robert A" uniqKey="Schwartz R" first="Robert A." last="Schwartz">Robert A. Schwartz</name><affiliation><mods:affiliation>Dermatology and Pathology, New Jersey Medical School, NJ, Newark, USA</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">International Journal of Dermatology</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF DERMATOLOGY</title><idno type="ISSN">0011-9059</idno><idno type="eISSN">1365-4632</idno><imprint><biblScope unit="vol">52</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="666">666</biblScope><biblScope unit="page" to="672">672</biblScope><biblScope unit="page-count">7</biblScope><date type="published" when="2013-06">2013-06</date></imprint><idno type="ISSN">0011-9059</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0011-9059</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Kaposi's sarcoma (KS) is an important mucocutaneous neoplasm with four well‐known clinicopathologic types. Involvement of the oral cavity may be seen in all variants but is most common with AIDS‐KS. The latter may signal undiagnosed HIV infection. Its common association with disseminated disease has potentially important diagnostic and therapeutic implications. Oral KS (OKS) most often affects the hard and soft palate, gingiva, and dorsal tongue with plaques or tumors of coloration ranging from non‐pigmented to brownish‐red or violaceous. Its involvement ranges from an incidental finding to proliferative tumor formation that interferes with mastication. OKS needs to be distinguished clinically from other entities, including pyogenic granuloma, hemangioma, bacillary angiomatosis, and gingival enlargement caused by cyclosporine, a drug frequently used in recipients of organ transplantation. KS may flare as part of the immune reconstitution inflammatory syndrome in HIV patients or develop in the context of iatrogenic immunosuppression. Management, which may depend upon a variety of factors including the clinicopathologic type of KS and results of staging, ranges from no treatment to local measures such as intralesional vinblastine or systemic administration of cytotoxic chemotherapy for disseminated disease. Modification of immunosuppressive regimens often helps control post‐transplant OKS but enhances the risk of graft rejection. Screening donors and recipients of organ transplants for HHV‐8, with prophylactic treatment if infected as well as institution of sirolimus early after transplantation, are proposed strategies aimed at preventing post‐transplant OKS.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>sarcoma</json:string><json:string>kaposi</json:string><json:string>dermatology</json:string><json:string>oral cavity</json:string><json:string>immunosuppressive</json:string><json:string>kaposi sarcoma</json:string><json:string>oral sarcoma</json:string><json:string>transplantation</json:string><json:string>intralesional</json:string><json:string>endemic</json:string><json:string>haart</json:string><json:string>vinblastine</json:string><json:string>gingival</json:string><json:string>fatahzadeh</json:string><json:string>international society</json:string><json:string>iatrogenic</json:string><json:string>exophytic</json:string><json:string>immune</json:string><json:string>sirolimus</json:string><json:string>human herpesvirus</json:string><json:string>bacillary angiomatosis</json:string><json:string>oral pathol</json:string><json:string>organ transplant</json:string><json:string>transplant</json:string><json:string>immunosuppressive regimens</json:string><json:string>systemic administration</json:string><json:string>case report</json:string><json:string>international journal</json:string><json:string>immune reconstitution syndrome</json:string><json:string>regimen</json:string><json:string>lesion</json:string><json:string>intralesional vinblastine</json:string><json:string>immunosuppressive regimen</json:string><json:string>pyogenic granuloma</json:string><json:string>oral lesions</json:string><json:string>oral surg</json:string><json:string>oral maxillofac surg</json:string><json:string>gingival enlargement</json:string><json:string>palate</json:string><json:string>oral prostheses</json:string><json:string>oral oncol</json:string><json:string>immune syndrome</json:string><json:string>spindle cells</json:string><json:string>oral medicine</json:string><json:string>active antiretroviral therapy</json:string><json:string>organ transplants</json:string><json:string>systemic chemotherapy</json:string><json:string>immunosuppressive therapy</json:string><json:string>transplant recipients</json:string><json:string>local therapy</json:string><json:string>sarcoma fatahzadeh</json:string><json:string>vinca alkaloids</json:string><json:string>oral etoposide</json:string><json:string>acute graft rejection</json:string><json:string>dorsal tongue</json:string><json:string>soft palate</json:string><json:string>oral kaposi sarcoma</json:string><json:string>higher mortality rate</json:string><json:string>local measures</json:string><json:string>cutaneous sarcoma</json:string><json:string>oral mucosa</json:string><json:string>other variants</json:string><json:string>therapeutic approaches</json:string><json:string>systemic</json:string></teeft></keywords><author><json:item><name>Mahnaz Fatahzadeh DMD, MSD</name><affiliations><json:string>Oral Medicine, New Jersey Dental School, NJ, Newark, USA</json:string><json:string>Mahnaz Fatahzadeh, ,Division of Oral MedicineNew Jersey Dental School110 Bergen StreetNewark, NJ 07103‐2714, USAE‐mail:</json:string><json:string>E-mail: fatahza@umdnj.edu</json:string></affiliations></json:item><json:item><name>Robert A. Schwartz MD, MPH, FRCP (Edin)</name><affiliations><json:string>Dermatology and Pathology, New Jersey Medical School, NJ, Newark, USA</json:string></affiliations></json:item></author><articleId><json:string>IJD5758</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>reviewArticle</json:string></originalGenre><abstract>Kaposi's sarcoma (KS) is an important mucocutaneous neoplasm with four well‐known clinicopathologic types. Involvement of the oral cavity may be seen in all variants but is most common with AIDS‐KS. The latter may signal undiagnosed HIV infection. Its common association with disseminated disease has potentially important diagnostic and therapeutic implications. Oral KS (OKS) most often affects the hard and soft palate, gingiva, and dorsal tongue with plaques or tumors of coloration ranging from non‐pigmented to brownish‐red or violaceous. Its involvement ranges from an incidental finding to proliferative tumor formation that interferes with mastication. OKS needs to be distinguished clinically from other entities, including pyogenic granuloma, hemangioma, bacillary angiomatosis, and gingival enlargement caused by cyclosporine, a drug frequently used in recipients of organ transplantation. KS may flare as part of the immune reconstitution inflammatory syndrome in HIV patients or develop in the context of iatrogenic immunosuppression. Management, which may depend upon a variety of factors including the clinicopathologic type of KS and results of staging, ranges from no treatment to local measures such as intralesional vinblastine or systemic administration of cytotoxic chemotherapy for disseminated disease. Modification of immunosuppressive regimens often helps control post‐transplant OKS but enhances the risk of graft rejection. Screening donors and recipients of organ transplants for HHV‐8, with prophylactic treatment if infected as well as institution of sirolimus early after transplantation, are proposed strategies aimed at preventing post‐transplant OKS.</abstract><qualityIndicators><score>8.943</score><pdfVersion>1.7</pdfVersion><pdfPageSize>595.276 x 782.362 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1685</abstractCharCount><pdfWordCount>4171</pdfWordCount><pdfCharCount>27987</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>231</abstractWordCount></qualityIndicators><title>Oral Kaposi's sarcoma: a review and update</title><genre><json:string>review-article</json:string></genre><host><title>International Journal of Dermatology</title><language><json:string>unknown</json:string></language><doi><json:string>10.1111/(ISSN)1365-4632</json:string></doi><issn><json:string>0011-9059</json:string></issn><eissn><json:string>1365-4632</json:string></eissn><publisherId><json:string>IJD</json:string></publisherId><volume>52</volume><issue>6</issue><pages><first>666</first><last>672</last><total>7</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Review</value></json:item></subject></host><categories><wos><json:string>science</json:string><json:string>dermatology</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>dermatology & venereal diseases</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2013</publicationDate><copyrightDate>2013</copyrightDate><doi><json:string>10.1111/j.1365-4632.2012.05758.x</json:string></doi><id>E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Oral Kaposi's sarcoma: a review and update</title></titleStmt><publicationStmt><publisher>Blackwell Publishing Ltd</publisher><availability><licence>© 2013 The International Society of Dermatology</licence></availability><date type="published" when="2013-06"></date></publicationStmt><notesStmt><note type="content-type" subtype="review-article" source="reviewArticle" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-L5L7X3NF-P">review-article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="review-article"><analytic><title level="a" type="main">Oral Kaposi's sarcoma: a review and update</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Mahnaz</forename><surname>Fatahzadeh</surname><roleName type="degree">DMD, MSD</roleName></persName><affiliation><orgName>Oral Medicine</orgName><orgName>New Jersey Dental School</orgName><address><settlement type="city">Newark</settlement><region>NJ</region><country key="US">USA</country></address></affiliation><affiliation>Correspondence Mahnaz Fatahzadeh, dmd, msd Division of Oral Medicine New Jersey Dental School 110 Bergen Street Newark, NJ 07103‐2714, USA E‐mail: fatahza@umdnj.edu</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Robert A.</forename><surname>Schwartz</surname><roleName type="degree">MD, MPH, FRCP (Edin)</roleName></persName><affiliation><orgName>Dermatology and Pathology</orgName><orgName>New Jersey Medical School</orgName><address><settlement type="city">Newark</settlement><region>NJ</region><country key="US">USA</country></address></affiliation></author><idno type="istex">E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA</idno><idno type="DOI">10.1111/j.1365-4632.2012.05758.x</idno><idno type="unit">IJD5758</idno><idno type="toTypesetVersion">file:IJD.IJD5758.pdf</idno></analytic><monogr><title level="j" type="main">International Journal of Dermatology</title><title level="j" type="alt">INTERNATIONAL JOURNAL OF DERMATOLOGY</title><idno type="pISSN">0011-9059</idno><idno type="eISSN">1365-4632</idno><idno type="book-DOI">10.1111/(ISSN)1365-4632</idno><idno type="book-part-DOI">10.1111/ijd.2013.52.issue-6</idno><idno type="product">IJD</idno><imprint><biblScope unit="vol">52</biblScope><biblScope unit="issue">6</biblScope><biblScope unit="page" from="666">666</biblScope><biblScope unit="page" to="672">672</biblScope><biblScope unit="page-count">7</biblScope><date type="published" when="2013-06"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><abstract xml:lang="en" style="main" xml:id="ijd5758-abs-0001"><head>Abstract</head><p>Kaposi's sarcoma (<hi rend="fc">KS</hi>) is an important mucocutaneous neoplasm with four well‐known clinicopathologic types. Involvement of the oral cavity may be seen in all variants but is most common with <hi rend="fc">AIDS</hi>‐<hi rend="fc">KS</hi>. The latter may signal undiagnosed <hi rend="fc">HIV</hi> infection. Its common association with disseminated disease has potentially important diagnostic and therapeutic implications. Oral <hi rend="fc">KS</hi> (<hi rend="fc">OKS</hi>) most often affects the hard and soft palate, gingiva, and dorsal tongue with plaques or tumors of coloration ranging from non‐pigmented to brownish‐red or violaceous. Its involvement ranges from an incidental finding to proliferative tumor formation that interferes with mastication. <hi rend="fc">OKS</hi> needs to be distinguished clinically from other entities, including pyogenic granuloma, hemangioma, bacillary angiomatosis, and gingival enlargement caused by cyclosporine, a drug frequently used in recipients of organ transplantation. <hi rend="fc">KS</hi> may flare as part of the immune reconstitution inflammatory syndrome in <hi rend="fc">HIV</hi> patients or develop in the context of iatrogenic immunosuppression. Management, which may depend upon a variety of factors including the clinicopathologic type of <hi rend="fc">KS</hi> and results of staging, ranges from no treatment to local measures such as intralesional vinblastine or systemic administration of cytotoxic chemotherapy for disseminated disease. Modification of immunosuppressive regimens often helps control post‐transplant <hi rend="fc">OKS</hi> but enhances the risk of graft rejection. Screening donors and recipients of organ transplants for <hi rend="fc">HHV</hi>‐8, with prophylactic treatment if infected as well as institution of sirolimus early after transplantation, are proposed strategies aimed at preventing post‐transplant <hi rend="fc">OKS</hi>.</p></abstract><textClass><classCode scheme="articleCategory">Review</classCode><classCode scheme="tocHeading1">Review</classCode></textClass><langUsage><language ident="EN"></language></langUsage></profileDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component type="serialArticle" version="2.0" xml:id="ijd5758" xml:lang="en"><header><publicationMeta level="product"><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-4632</doi><issn type="print">0011-9059</issn><issn type="electronic">1365-4632</issn><idGroup><id type="product" value="IJD"></id></idGroup><titleGroup><title sort="INTERNATIONAL JOURNAL OF DERMATOLOGY" type="main">International Journal of Dermatology</title><title type="short">Int J Dermatol</title></titleGroup></publicationMeta><publicationMeta level="part" position="06106"><doi origin="wiley">10.1111/ijd.2013.52.issue-6</doi><copyright ownership="thirdParty">© 2013 International Society of Dermatology</copyright><numberingGroup><numbering number="52" type="journalVolume">52</numbering><numbering type="journalIssue">6</numbering></numberingGroup><coverDate startDate="2013-06">June 2013</coverDate></publicationMeta><publicationMeta level="unit" position="4" status="forIssue" type="reviewArticle"><doi>10.1111/j.1365-4632.2012.05758.x</doi><idGroup><id type="unit" value="IJD5758"></id></idGroup><countGroup><count number="7" type="pageTotal"></count></countGroup><titleGroup><title type="articleCategory">Review</title><title type="tocHeading1">Review</title></titleGroup><copyright ownership="thirdParty">© 2013 The International Society of Dermatology</copyright><eventGroup><event agent="SPS" date="2012-07-21" type="xmlCreated"></event><event type="firstOnline" date="2013-05-17"></event><event type="publishedOnlineFinalForm" date="2013-05-17"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-13"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.6.4 mode:FullText" date="2015-10-02"></event></eventGroup><numberingGroup><numbering type="pageFirst">666</numbering><numbering type="pageLast">672</numbering></numberingGroup><correspondenceTo><lineatedText><line><b>Correspondence</b></line><line>Mahnaz Fatahzadeh, <sc>dmd</sc>,<sc> msd</sc></line><line>Division of Oral Medicine</line><line>New Jersey Dental School</line><line>110 Bergen Street</line><line>Newark, NJ 07103‐2714, USA</line><line>E‐mail: <email>fatahza@umdnj.edu</email></line></lineatedText></correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:IJD.IJD5758.pdf"></link></linkGroup></publicationMeta><contentMeta><titleGroup><title type="main">Oral Kaposi's sarcoma: a review and update</title><title type="shortAuthors"><i>Fatahzadeh and Schwartz</i></title></titleGroup><creators><creator affiliationRef="#ijd5758-aff-0001" corresponding="yes" creatorRole="author" xml:id="ijd5758-cr-0001"><personName><givenNames>Mahnaz</givenNames> <familyName>Fatahzadeh</familyName> <degrees>DMD, MSD</degrees></personName></creator><creator affiliationRef="#ijd5758-aff-0002" creatorRole="author" xml:id="ijd5758-cr-0002"><personName><givenNames>Robert A.</givenNames> <familyName>Schwartz</familyName> <degrees>MD, MPH, FRCP (Edin)</degrees></personName></creator></creators><affiliationGroup><affiliation countryCode="US" type="organization" xml:id="ijd5758-aff-0001"><orgDiv>Oral Medicine</orgDiv> <orgName>New Jersey Dental School</orgName><address><city>Newark</city> <countryPart>NJ</countryPart> <country>USA</country></address></affiliation><affiliation countryCode="US" type="organization" xml:id="ijd5758-aff-0002"><orgDiv>Dermatology and Pathology</orgDiv> <orgName>New Jersey Medical School</orgName> <address><city>Newark</city> <countryPart>NJ</countryPart> <country>USA</country></address></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:id="ijd5758-abs-0001" xml:lang="en"><title type="main">Abstract</title><p>Kaposi's sarcoma (<fc>KS</fc>) is an important mucocutaneous neoplasm with four well‐known clinicopathologic types. Involvement of the oral cavity may be seen in all variants but is most common with <fc>AIDS</fc>‐<fc>KS</fc>. The latter may signal undiagnosed <fc>HIV</fc> infection. Its common association with disseminated disease has potentially important diagnostic and therapeutic implications. Oral <fc>KS</fc> (<fc>OKS</fc>) most often affects the hard and soft palate, gingiva, and dorsal tongue with plaques or tumors of coloration ranging from non‐pigmented to brownish‐red or violaceous. Its involvement ranges from an incidental finding to proliferative tumor formation that interferes with mastication. <fc>OKS</fc> needs to be distinguished clinically from other entities, including pyogenic granuloma, hemangioma, bacillary angiomatosis, and gingival enlargement caused by cyclosporine, a drug frequently used in recipients of organ transplantation. <fc>KS</fc> may flare as part of the immune reconstitution inflammatory syndrome in <fc>HIV</fc> patients or develop in the context of iatrogenic immunosuppression. Management, which may depend upon a variety of factors including the clinicopathologic type of <fc>KS</fc> and results of staging, ranges from no treatment to local measures such as intralesional vinblastine or systemic administration of cytotoxic chemotherapy for disseminated disease. Modification of immunosuppressive regimens often helps control post‐transplant <fc>OKS</fc> but enhances the risk of graft rejection. Screening donors and recipients of organ transplants for <fc>HHV</fc>‐8, with prophylactic treatment if infected as well as institution of sirolimus early after transplantation, are proposed strategies aimed at preventing post‐transplant <fc>OKS</fc>.</p></abstract></abstractGroup></contentMeta><noteGroup xml:id="ijd5758-ntgp-0001"><note numbered="no" xml:id="ijd5758-note-0001">Funding: None.</note><note numbered="no" xml:id="ijd5758-note-0002">Conflicts of interest: None.</note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Oral Kaposi's sarcoma: a review and update</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Oral Kaposi's sarcoma: a review and update</title></titleInfo><name type="personal"><namePart type="given">Mahnaz</namePart><namePart type="family">Fatahzadeh</namePart><namePart type="termsOfAddress">DMD, MSD</namePart><affiliation>Oral Medicine, New Jersey Dental School, NJ, Newark, USA</affiliation><affiliation>Mahnaz Fatahzadeh, ,Division of Oral MedicineNew Jersey Dental School110 Bergen StreetNewark, NJ 07103‐2714, USAE‐mail: </affiliation><affiliation>E-mail: fatahza@umdnj.edu</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Robert A.</namePart><namePart type="family">Schwartz</namePart><namePart type="termsOfAddress">MD, MPH, FRCP (Edin)</namePart><affiliation>Dermatology and Pathology, New Jersey Medical School, NJ, Newark, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="reviewArticle"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><dateIssued encoding="w3cdtf">2013-06</dateIssued><dateCreated encoding="w3cdtf">2012-07-21</dateCreated><copyrightDate encoding="w3cdtf">2013</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">Kaposi's sarcoma (KS) is an important mucocutaneous neoplasm with four well‐known clinicopathologic types. Involvement of the oral cavity may be seen in all variants but is most common with AIDS‐KS. The latter may signal undiagnosed HIV infection. Its common association with disseminated disease has potentially important diagnostic and therapeutic implications. Oral KS (OKS) most often affects the hard and soft palate, gingiva, and dorsal tongue with plaques or tumors of coloration ranging from non‐pigmented to brownish‐red or violaceous. Its involvement ranges from an incidental finding to proliferative tumor formation that interferes with mastication. OKS needs to be distinguished clinically from other entities, including pyogenic granuloma, hemangioma, bacillary angiomatosis, and gingival enlargement caused by cyclosporine, a drug frequently used in recipients of organ transplantation. KS may flare as part of the immune reconstitution inflammatory syndrome in HIV patients or develop in the context of iatrogenic immunosuppression. Management, which may depend upon a variety of factors including the clinicopathologic type of KS and results of staging, ranges from no treatment to local measures such as intralesional vinblastine or systemic administration of cytotoxic chemotherapy for disseminated disease. Modification of immunosuppressive regimens often helps control post‐transplant OKS but enhances the risk of graft rejection. Screening donors and recipients of organ transplants for HHV‐8, with prophylactic treatment if infected as well as institution of sirolimus early after transplantation, are proposed strategies aimed at preventing post‐transplant OKS.</abstract><relatedItem type="host"><titleInfo><title>International Journal of Dermatology</title></titleInfo><titleInfo type="abbreviated"><title>Int J Dermatol</title></titleInfo><genre type="journal">journal</genre><subject><genre>article-category</genre><topic>Review</topic></subject><identifier type="ISSN">0011-9059</identifier><identifier type="eISSN">1365-4632</identifier><identifier type="DOI">10.1111/(ISSN)1365-4632</identifier><identifier type="PublisherID">IJD</identifier><part><date>2013</date><detail type="volume"><caption>vol.</caption><number>52</number></detail><detail type="issue"><caption>no.</caption><number>6</number></detail><extent unit="pages"><start>666</start><end>672</end><total>7</total></extent></part></relatedItem><identifier type="istex">E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA</identifier><identifier type="DOI">10.1111/j.1365-4632.2012.05758.x</identifier><identifier type="ArticleID">IJD5758</identifier><accessCondition type="use and reproduction" contentType="copyright">© 2013 International Society of Dermatology© 2013 The International Society of Dermatology</accessCondition><recordInfo><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006B93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 006B93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:E5C9A6A162C267E19069C7F79B67AE9D96EFC3EA
|texte= Oral Kaposi's sarcoma: a review and update
}}
| This area was generated with Dilib version V0.6.31. |  |